BioSpaceOriginal article
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
Phase 2negativeemugrobartNegative
AI Analysis
Summary
Roche discontinued development of emugrobart, an anti-myostatin obesity drug, after an interim mid-stage analysis indicated it was unlikely to produce meaningful weight loss, returning the asset rights to subsidiary Chugai Pharmaceutical.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
interim mid-stage analysis showed anti-myostatin therapy unlikely to elicit meaningful weight loss
Importance:7/10
Sentiment:
-0.85
obesityanti-myostatinclinical_failureasset_returnmid-stage
Read the original article
Published by BioSpace on September 29, 2026 2:13 PM